Esophageal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Esophageal cancer is the seventh leading cause of death in males in the United States (US). Squamous cell carcinoma is the most common histology for EC worldwide; however, adenocarcinoma is the most predominant histology in the US. Early-stage EC may be totally asymptomatic or may present with mild nonspecific symptoms such as heartburn, atypical chest pain, or dyspepsia. Alternatively, patients may present with symptoms such as occult blood in the stool or iron deficiency anemia. Patients may report mild or intermittent dysphagia, odynophagia, or a foreign body sensation. These symptoms generally warrant diagnostic evaluation, including an esophagogastroduodenoscopy (EGD) (upper endoscopy), including a diagnostic mucosal biopsy. Some early cancers are diagnosed during routine upper endoscopic surveillance of Barrett’s esophagus. The symptoms of EC generally progress rapidly.

·       The overall incidence of esophageal cancer (EC) ranges between 4.7 to 5.8 per 100,000 people per year. Males had a higher incidence of EC than females.

 

Thelansis’s “Esophageal Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Esophageal Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Esophageal Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Esophageal Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Esophageal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Esophageal Cancer, Esophageal Cancer market outlook, Esophageal Cancer competitive landscape, Esophageal Cancer market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)